Gilead Sciences (GILD)

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations.

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.

The company is eyeing FDA approval for its drug, lenacapavir, for HIV prevention by mid-June.

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off?

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade tensions boosts risk sentiment.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

A fundamental analysis of (NASDAQ:GILD) shows GILEAD SCIENCES INC (NASDAQ:GILD) may be suited for quality investing, we'll explore why in this article.